Abstract:Autism Spectrum Disorder (ASD) is a synaptic disorder with a GABA/glutamate imbalance in the perineuronal nets and structural abnormalities such as increased dendritic spines and decreased long distance connections. Specific pregnancy disorders significantly increase the risk for an ASD phenotype such as preeclampsia, preterm birth, hypoxia phenomena, and spontaneous miscarriages. They are associated with defects in the glycosylation-immune placental processes implicated in neurogenesis. Some glycans epitopes expressed in the placenta, and specifically in the extra-villous trophoblast also have predominant functions in dendritic process and synapse function. Among these, the most important are CD57 or HNK1, CD22, CD24, CD33 and CD45. They modulate the innate immune cells at the maternal-fetal interface and they promote foeto-maternal tolerance. There are many glycan-based pathways of immunosuppression. N-glycosylation pathway dysregulation has been found to be associated with autoimmune-like phenotypes and maternal-autoantibody-related (MAR) autism have been found to be associated with central, systemic and peripheric autoimmune processes. Essential molecular pathways associated with the glycan-epitopes expression have been found to be specifically dysregulated in ASD, notably the Slit/Robo, Wnt, and mTOR/RAGE signaling pathways. These modifications have important effects on major transcriptional pathways with important genetic expression consequences. These modifications lead to defects in neuronal progenitors and in the nervous system's implementation specifically, with further molecular defects in the GABA/glutamate system. Glycosylation placental processes are crucial effectors for proper maternofetal immunity and endocrine/paracrine pathways formation. Glycans/ galectins expression regulate immunity and neurulation processes with a direct link with gene expression. These need to be clearly elucidated in ASD pathophysiology.

Glycosylation and behavioral symptoms in neurological disorders

O-GlcNAcylation, a Sweet Link to the Pathology of Diseases

O-GlcNAcylation and Its Roles in Neurodegenerative Diseases

Congenital Disorders of Glycosylation from a Neurological Perspective

N-Glycosylation as a Modulator of Protein Conformation and Assembly in Disease

The alteration and role of glycoconjugates in Alzheimer's disease

Aberrant glycosylation in schizophrenia: insights into pathophysiological mechanisms and therapeutic potentials

Glycosylation in aging and neurodegenerative diseases

The role of protein glycosylation in Alzheimer disease

Neuronal loss of Impairs O-glycosylation and Leads to Neurobehavioral Deficits Mimicking GALNT2-CDG

Glycosylation: mechanisms, biological functions and clinical implications

The Role of O-GlcNAcation in Neurodevelopment and Nerve System Diseases

Emerging roles of O-glycosylation in regulating protein aggregation, phase separation, and functions

Glycosylation enzyme mRNA expression in dorsolateral prefrontal cortex of elderly patients with schizophrenia: Evidence for dysregulation of multiple glycosylation pathways

Glycosylation in Cellular Mechanisms of Health and Disease

Molecular and Cellular Insights: A Focus on Glycans and the HNK1 Epitope in Autism Spectrum Disorder

New Insight into Protein Glycosylation in the Development of Alzheimer’s Disease

Aberrant Ganglioside Functions to Underpin Dysregulated Myelination, Insulin Signalling, and Cytokine Expression: Is There a Link and a Room for Therapy?

The role of protein glycosylation in muscle diseases

Role of O-GlcNAcylation in Central Nervous System Development and Injuries: A Systematic Review

Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach